Real-World Healthcare Resource Use Associated with Recurrent or Metastatic Head and Neck Cancer Patients Care in Portugal-TRACE Study

被引:0
作者
Teixeira, Maria Margarida [1 ]
Dias, Joao [2 ]
Andre, Teresa [3 ]
Joaquim, Ana [4 ]
Fernandes, Ricardo [5 ]
Magalhaes, Joana [6 ]
Marreiros, Laura [7 ]
Pinto, Leonor [8 ]
Ribeiro, Leonor [9 ]
Nogueira, Mafalda [10 ]
Morais, Catarina [10 ]
机构
[1] Inst Portugues Oncol Coimbra Francisco Gentil, P-3000075 Coimbra, Portugal
[2] Inst Portugues Oncol Porto Francisco Gentil, P-4200072 Porto, Portugal
[3] Hosp Dr Nelio Mendonca, P-9000177 Funchal, Portugal
[4] Unidade Local Saude Gaia Espinho, P-4434502 Vila Nova De Gaia, Portugal
[5] Unidade Local Saude Braga, P-4710243 Braga, Portugal
[6] Unidade Local Saude Algarve, P-8000386 Faro, Portugal
[7] Unidade Local Saude Almada Seixal, P-2805267 Almada, Portugal
[8] Unidade Local Saude Coimbra, P-3004561 Coimbra, Portugal
[9] Unidade Local Saude Santa Maria, P-1649035 Lisbon, Portugal
[10] MSD Portugal, Paco De Arcos, Portugal
关键词
head and neck; recurrent or metastatic disease; real-world; healthcare resources; patient management; SQUAMOUS-CELL CARCINOMA; GUIDELINES(R) INSIGHTS HEAD; RECURRENT/METASTATIC HEAD; PEMBROLIZUMAB; CHEMOTHERAPY; EPIDEMIOLOGY; KEYNOTE-048; CETUXIMAB; RISK;
D O I
10.3390/curroncol31080318
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) is a challenging disease, requiring personalized management by a multidisciplinary team. The aim of this retrospective multicentric study was to characterize real-world healthcare resource use and patient care for R/M HNSCC in Portugal during the first year after diagnosis. A total of 377 patients ineligible for curative treatment were included, mostly male (92.8%), aged 50-69 years (74.5%), with heavy alcohol (72.7%) or smoking habits (89.3%). Oropharynx (33.2%) and oral cavity (28.7%) were primary tumor locations, with lung metastases being the most common (61.4%). Eligible patients for systemic treatment with palliative intent (80.6%) received up to four treatment lines, with varied regimens. Platinum-based combination chemotherapy dominated first-line treatment (>70%), while single-agent chemotherapy and anti-PD1 immunotherapy were prevalent in later lines. Treatment approaches were uniform across disease stages and primary tumor locations but varied geographically. Treated patients received more multidisciplinary support than those who were ineligible. This study provides the first Portuguese real-world description of R/M HNSCC patient characteristics, treatment patterns, and supportive care during the year after diagnosis, highlighting population heterogeneity and aiming to improve patient management.
引用
收藏
页码:4270 / 4283
页数:14
相关论文
共 28 条
  • [1] Real-world treatment patterns, cost of care and effectiveness of therapies for patients with squamous cell carcinoma of head and neck pre and post approval of immuno-oncology agents
    Abraham, Pranav
    Kish, Jonathan Karl
    Korytowsky, Beata
    Radtchenko, Janna
    Singh, Prianka
    Shaw, James
    Feinberg, Bruce
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (02) : 125 - 131
  • [2] NCCN Guidelines® Insights Head and Neck Cancers, Version 2.2017
    Adelstein, David
    Gillison, Maura L.
    Pfister, David G.
    Spencer, Sharon
    Adkins, Douglas
    Brizel, David M.
    Burtness, Barbara
    Busse, Paul M.
    Caudell, Jimmy J.
    Cmelak, Anthony J.
    Colevas, A. Dimitrios
    Eisele, David W.
    Fenton, Moon
    Foote, Robert L.
    Gilbert, Jill
    Haddad, Robert I.
    Hicks, Wesley L., Jr.
    Hitchcock, Ying J.
    Jimeno, Antonio
    Leizman, Debra
    Lydiatt, William M.
    Maghami, Ellie
    Mell, Loren K.
    Mittal, Bharat B.
    Pinto, Harlan A.
    Ridge, John A.
    Rocco, James
    Rodriguez, Cristina P.
    Shah, Jatin P.
    Weber, Randal S.
    Witek, Matthew
    Worden, Frank
    Yom, Sue S.
    Zhen, Weining
    Burns, Jennifer L.
    Darlow, Susan D.
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2017, 15 (06): : 761 - 770
  • [3] Immunotherapy for recurrent/metastatic head and neck cancer
    Alfieri, Salvatore
    Cavalieri, Stefano
    Licitra, Lisa
    [J]. CURRENT OPINION IN OTOLARYNGOLOGY & HEAD AND NECK SURGERY, 2018, 26 (02) : 152 - 156
  • [4] Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score
    Burtness, Barbara
    Rischin, Danny
    Greil, Richard
    Soulieres, Denis
    Tahara, Makoto
    de Castro Jr, Gilberto
    Psyrri, Amanda
    Brana, Irene
    Baste, Neus
    Neupane, Prakash
    Bratland, Ase
    Fuereder, Thorsten
    Hughes, Brett G. M.
    Mesia, Ricard
    Ngamphaiboon, Nuttapong
    Rordorf, Tamara
    Wan Ishak, Wan Zamaniah
    Ge, Joy
    Swaby, Ramona F.
    Gumuscu, Burak
    Harrington, Kevin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (21) : 2321 - +
  • [5] Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
    Burtness, Barbara
    Harrington, Kevin J.
    Greil, Richard
    Soulieres, Denis
    Tahara, Makoto
    de Castro, Gilberto, Jr.
    Psyrri, Amanda
    Baste, Neus
    Neupane, Prakash
    Bratland, Ase
    Fuereder, Thorsten
    Hughes, Brett G. M.
    Mesia, Ricard
    Ngamphaiboon, Nuttapong
    Rordorf, Tamara
    Ishak, Wan Zamaniah Wan
    Hong, Ruey-Long
    Mendoza, Rene Gonzalez
    Roy, Ananya
    Zhang, Yayan
    Gumuscu, Burak
    Cheng, Jonathan D.
    Jin, Fan
    Rischin, Danny
    [J]. LANCET, 2019, 394 (10212) : 1915 - 1928
  • [6] Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
    Cohen, Ezra E. W.
    Soulieres, Denis
    Le Tourneau, Christophe
    Dinis, Jose
    Licitra, Lisa
    Ahn, Myung-Ju
    Soria, Ainara
    Machiels, Jean-Pascal
    Mach, Nicolas
    Mehra, Ranee
    Burtness, Barbara
    Zhang, Pingye
    Cheng, Jonathan
    Swaby, Ramona F.
    Harrington, Kevin J.
    [J]. LANCET, 2019, 393 (10167) : 156 - 167
  • [7] NCCN Guidelines® Insights Head and Neck Cancers, Version 1.2018 Featured Updates to the NCCN Guidelines
    Colevas, A. Dimitrios
    Yom, Sue S.
    Pfister, David G.
    Spencer, Sharon
    Adelstein, David
    Adkins, Douglas
    Brizel, David M.
    Burtness, Barbara
    Busse, Paul M.
    Caudell, Jimmy J.
    Cmelak, Anthony J.
    Eisele, David W.
    Fenton, Moon
    Foote, Robert L.
    Gilbert, Jill
    Gillison, Maura L.
    Haddad, Robert I.
    Hicks, Wesley L., Jr.
    Hitchcock, Ying J.
    Jimeno, Antonio
    Leizman, Debra
    Maghami, Ellie
    Mell, Loren K.
    Mittal, Bharat B.
    Pinto, Harlan A.
    Ridge, John A.
    Rocco, James
    Rodriguez, Cristina P.
    Shah, Jatin P.
    Weber, Randal S.
    Witek, Matthew
    Worden, Frank
    Zhen, Weining
    Burns, Jennifer L.
    Darlow, Susan D.
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2018, 16 (05): : 479 - 490
  • [8] Patients’ experience of recurrent/metastatic head and neck squamous cell carcinoma and their perspective on the eortc qlq-c30 and qlq-h&n35 questionnaires: A qualitative study
    Degboe A.
    Knight S.L.
    Halling K.
    Trigg A.
    Al-Zubeidi T.
    Aldhouse N.
    Kitchen H.
    Wirth L.
    Rogers S.N.
    [J]. Journal of Patient-Reported Outcomes, 2 (1)
  • [9] Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
    Ferris, R. L.
    Blumenschein, G., Jr.
    Fayette, J.
    Guigay, J.
    Colevas, A. D.
    Licitra, L.
    Harrington, K.
    Kasper, S.
    Vokes, E. E.
    Even, C.
    Worden, F.
    Saba, N. F.
    Iglesias Docampo, L. C.
    Haddad, R.
    Rordorf, T.
    Kiyota, N.
    Tahara, M.
    Monga, M.
    Lynch, M.
    Geese, W. J.
    Kopit, J.
    Shaw, J. W.
    Gillison, M. L.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19) : 1856 - 1867
  • [10] Patient Characteristics and Costs in Recurrent or Refractory Head and Neck Cancer: Retrospective Analysis of a Community Oncology Database
    Fisher, Maxine D.
    Fernandes, Ancilla W.
    Olufade, Temitope O.
    Miller, Paul J.
    Walker, Mark S.
    Fenton, Moon
    [J]. CLINICAL THERAPEUTICS, 2018, 40 (04) : 562 - 573